EQL Pharma launch a combined Covid-19 and influenza A/B antigen self-test

EQL Pharma has today, as an exclusive supplier, launched a brand new combined Covid-19 and influenza (A+B) antigen self-test from Alltest. With a single sampling from the nasal cavity, the test detects Covid-19 and/or influenza (type A and B – the most common variants). The test is of great use in circumstances where it is important to determine which virus that caused the infection, to be able to foresee potential outcomes, risks, and decide on treatment options.

The self-test has 96,99% sensitivity to Covid-19, 95,77% sensitivity to influenza type A and 94,12% sensitivity to the less common influenza type B. For more information on the use of the self-test there is an instruction video available on YouTube.

The test is CE marked and sensitive to all known variants of the Covid-19 virus, including Omicron BA.5 which is now the most common variant in Europe.

EQL Pharma is the exclusive supplier of this Alltest in the Nordics and in Ireland and the test is available in pharmacies.

For further information, please contact:
Axel Schörling
CEO & President, EQL Pharma AB (publ)

Phone: +46 (0) 763 – 17 90 60
E-mail: axel.schorling@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2022 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.